临床实践中双能X线吸收法骨密度检测间隔时间研究
结果显示平均间隔为36±21个月,仅11.1%的重复检测符合密集检测标准(间隔<23个月),密集检测比例从2006年16.7%降至2015年6.7%(趋势P<0.001)。
要点
- 重复DXA检测的平均间隔为36±21个月,仅11.1%符合密集检测标准(间隔<23个月)。
- 密集DXA检测比例从2006年的16.7%下降至2015年的6.7%(趋势P<0.001)。
- 任一解剖部位基线T值<-2.5与密集检测相关(OR 4.8;95%CI 4.0-5.7)。
核心结论
- 密集DXA检测的预测因素提示该做法优先用于具有多重危险因素的患者以及监测药物治疗反应,但过去十年间密集DXA检测在真实临床实践中已变得不那么常见。
- 需要进一步研究以更好地定义这一脆弱人群中骨密度检测的最佳使用。
研究设计与样本
- 研究分析了美国两个学术医学中心2004年至2017年间为监测目的进行的DXA检测时间间隔。
- 主要结局为检测间隔<23个月(称为「密集DXA检测」)。
- 采用广义线性混合模型评估所选患者层面临床因素与密集DXA检测之间的关联。
主要发现
- 重复DXA检测的平均时间间隔为36±21个月。
- 仅11.1%的重复DXA检测符合密集检测标准。
- 密集DXA检测百分比从2006年的16.7%下降至2015年的6.7%(趋势P<0.001)。
- 调整年龄、性别、门诊就诊次数和日历年之后,密集DXA检测的相关因素包括任一解剖部位基线T值<-2.5(OR 4.8;95%CI 4.0-5.7)、积极使用骨质疏松药物(OR 1.6;95%CI 1.3-1.9)和积极使用糖皮质激素(OR 1.3;95%CI 1.2-1.4)。
临床怎么用
- 原文结论指出密集DXA检测的预测因素提示该做法优先用于具有多重危险因素的患者以及监测药物治疗反应。
局限性
- 需要进一步研究以更好地定义这一脆弱人群中骨密度检测的最佳使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Intervals between dual-energy X-ray absorptiometry (DXA) scans were evaluated in a large cohort of typical clinical practice. Intensive DXA scanning (intervals < 23 months) decreased substantially, from 16.7% in 2006 to 6.7% in 2015. INTRODUCTION: Serial dual-energy X-ray absorptiometry (DXA) measurements are suggested for patients at high risk of fractures. However, little is known about how often DXA testing occurs in clinical practice. METHODS: We examined time intervals between DXA testing for monitoring purpose at two academic medical centers in the US between 2004 and 2017. The primary outcome was the presence of testing intervals < 23 months (termed "intensive DXA testing"). A generalized linear mixed model was used to evaluate the association between selected patient-level clinical factors and intensive DXA testing. RESULTS: Forty-nine thousand four hundred ninety-four DXA tests from 20,200 patients were analyzed. The mean time interval between scans was 36 ± 21 months. Only 11.1% of the repeated DXA testing met the criterion for intensive testing. The percentage of intensive DXA testing dropped from 16.7% in 2006 to 6.7% in 2015 (p for trend < 0.001). After adjusting for age, gender, number of outpatient visits, and calendar year, correlates of intensive DXA testing included a baseline T-score < -2.5 at any anatomic site (OR, 4.8; 95%CI, 4.0-5.7), active use of drugs for osteoporosis (OR, 1.6; 95%CI, 1.3-1.9), and active use of glucocorticoids (OR, 1.3; 95%CI, 1.2-1.4). CONCLUSIONS: The predictors of intensive DXA testing suggest that this practice is used preferentially in patients with multiple risk factors and to monitor the response to pharmacotherapy. However, intensive DXA testing has become less common in real-world clinical practice over the last decade. Further studies are required to better define the optimal use of bone mineral density testing in this vulnerable population.
引用
- Lyu H, Yoshida K, Tedeschi SK, et al. Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice. Osteoporos Int. 2019. PMID: 30680429. doi:10.1007/s00198-019-04847-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。